Cord blood platelet gel treatment of dystrophic recessive epidermolysis bullosa

Gianluca Tadini, Lidia Pezzani, Stefano Ghirardello, Paolo Rebulla, Susanna Esposito, Fabio Mosca

Research output: Contribution to journalArticlepeer-review

Abstract

Epidermolysis bullosa (EB) is comprised of a group of hereditary mechanobullous disorders that are characterised by extremely fragile skin and mucous membranes. This results in blister formation and nonhealing wounds. This case report describes the results of an innovative treatment of two large skin lesions in a newborn with dystrophic recessive EB (DEB) who experienced bacterial superinfections and progressive anaemisation. The lesions were treated with platelet gels derived from allogeneic cord blood (cord blood platelet gel, CBPGs). The skin lesions were clinically evaluated and treated with CBPG weekly until they completely healed. The first and second lesion required CBPG applications for 2 and 4 weeks, respectively. Both lesions were monitored weekly for 6 weeks after the last CBPG application, and no significant relapses were observed during the follow-up period. This case indicates that CBPG is an effective and safe therapeutic option for managing newborns with DEB, particularly as treatment and prevention of fluid loss and superinfection.

Original languageEnglish
Article number207364
JournalBMJ Case Reports
Volume2015
DOIs
Publication statusPublished - Jan 8 2015

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Cord blood platelet gel treatment of dystrophic recessive epidermolysis bullosa'. Together they form a unique fingerprint.

Cite this